Description: CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Home Page: cel-sci.com
8229 Boone Boulevard
Vienna,
VA
22182
United States
Phone:
703 506 9460
Officers
| Name | Title |
|---|---|
| Mr. Geert R. Kersten Esq. | CEO, Treasurer & Director |
| Ms. Patricia B. Prichep | Chief Financial and Operations Officer & Corporate Secretary |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer |
| Dr. Daniel H. Zimmerman Ph.D. | Senior Vice President of Research & Cellular Immunology |
| Mr. John Cipriano | Senior Vice President of Regulatory Affairs |
| Dr. Giovanni Selvaggi M.D. | Acting Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.0375 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |